Application of the model‐informed drug development paradigm to datopotamab deruxtecan dose selection for late‐stage development

Abstract To replace the conventional maximum tolerated dose (MTD) approach, a paradigm for dose optimization and dose selection that relies on model‐informed drug development (MIDD) approaches has been proposed in oncology. Here, we report our application of an MIDD approach during phase I to inform...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yasong Lu, Shuang Liang, Ying Hong, Naoyuki Tajima, Kashyap Patel, Hanbin Li, David R. Wada, Jon Greenberg, Adam Petrich, Hong Zebger‐Gong, Dale Shuster, Pavan Vaddady
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2024-01-01
coleção:	CPT: Pharmacometrics & Systems Pharmacology
Acesso em linha:	https://doi.org/10.1002/psp4.13058
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!